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ABSTRACT 
 
Objectives To investigate associations between obesity, changes in body mass index (BMI), 
alcohol intake and smoking status and the development of Psoriatic Arthritis (PsA) in people 
with psoriasis. 
Methods We have undertaken a cohort study involving incident psoriasis cases identified from 
the UK Clinical Practice Research Datalink between 1998 and 2014. The associations between 
smoking, alcohol and BMI and development of PsA were assessed using generalised additive 
models. Additionally, the risks associated with a change in BMI during follow-up were 
investigated using distributed lag non-linear models. 
Results We identified 90,189 incident cases of psoriasis (42% males, mean age 51) of whom 
1,409 had a subsequent record of PsA diagnosis. BMIs of 25.0-29.9, 30.0-34.9 and ≥35.0 were 
significantly associated with an increased risk of developing PsA compared to BMIs of <25.0: 
ORadj 1.79 (CI95 1.46 - 2.19), ORadj 2.10 (CI95 1.67 - 2.63), and ORadj 2.68 (CI95 2.09 - 3.43), 
respectively. Reducing BMI over a 10-year period (linearly) was associated with a reduction in 
the risk of developing PsA when compared to BMI remaining constant over the same period. 
Increased risks of developing PsA were associated with moderate drinking but not with ex- or 
heavy drinking or with current or past smoker status. 
Conclusion In this incident psoriasis cohort, increased BMI and moderate drinking but not heavy 
drinking or smoking status were associated with an increased risk of PsA in people with 
psoriasis. Importantly, we have shown that reducing weight may result in a reduction in the risk 
of developing PsA. 
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INTRODUCTION 
 
Psoriatic Arthritis (PsA) is a progressive and often destructive joint disease affecting 
approximately 20% of people with psoriasis.[1] PsA causes pain, swelling and joint stiffness and 
is accompanied by chronic disfiguring skin disease and can lead to an impaired quality of life.[2] 
For the majority of people with psoriasis, PsA is diagnosed after, or synchronously with, the 
onset of psoriasis,[3] identifying them as a target group for investigating modifiable risk factors in 
the development of PsA.  
 
While the association between obesity and an increased risk of psoriasis is well documented,[4] 
fewer studies have investigated its association with the risk of developing PsA. Three studies 
have found an increased risk of PsA among obese people with psoriasis, with the risk increasing 
with increasing body mass index (BMI).[5-7] However, these studies have only considered the 
effect of obesity as a single exposure whereas the effect of obesity on the risk of developing PsA 
in people with psoriasis may occur with some delay and may change over time. 
 
The role of smoking in the development of PsA is less clear with studies reporting conflicting 
results.[8-11] The conflicting results may relate to different study designs and timing of smoking 
measurement. While there is substantial evidence suggesting that alcohol intake is associated 
with risk of psoriasis, the relationship between alcohol intake and risk of PsA is less 
established.[12-17] Two studies have found an increase in alcohol consumption to be associated 
with an increase in the risk of developing PsA.[14, 15] Additional studies are therefore needed to 
better determine the role of smoking and alcohol in the development of PsA.  
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The aim of this study was to examine the associations between obesity, changes in BMI, alcohol 
consumption, smoking status and the development of PsA in people with psoriasis, using data 
from the Clinical Practice Research Datalink (CPRD). Understanding these modifiable risk 
factors is essential in determining those who are at the greatest risk of developing PsA, and 
hence will inform clinical recommendations on potential life-style adjustments that may reduce 
that risk.  
 
METHODS 
Data source 
The Clinical Practice Research Datalink (CPRD) contains routinely collected anonymised 
longitudinal medical records from UK primary care. It is actively collecting data on ~7% of the 
UK population.[18] It is generally representative of the UK population and has previously been 
used to study both psoriasis and PsA.[3, 19, 20] 
 
Study design 
A cohort study was performed of incident psoriasis cases identified from the CPRD, between 1 
January 1998 and 31 December 2014, and followed prospectively until the earliest of (a) the 
individual developing the outcome of interest PsA; (b) the individual or their practice ceasing to 
contribute data to the CPRD or (c) the end of the study period. 
 
Study population 
The base population consisted of all incident cases of psoriasis, aged 16 to 89 years at the time of 
diagnosis, who were permanently registered and contributing to the CPRD at any time during the 
study period, with at least one year of valid data collection.[18] 
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Identification of cases of psoriasis and PsA 
Incident cases of psoriasis diagnosed between 1998 and 2014 were identified, based on Read 
codes used and validated by previous studies in a similar UK database, which have been 
demonstrated to have a positive predictive value of 90%.[21, 22] In addition, psoriasis-specific 
treatment information was used as an indication of a psoriasis diagnosis (see online 
supplementary text). Cases were classified as incident if they had a minimum of one year of 
valid data collection before the date of diagnosis.[23]  
We searched the psoriasis cohort for incident cases of PsA diagnosed during the study period and 
after their date of psoriasis diagnosis using Read codes used and validated by a previous study, in 
a similar UK database, with a positive predictive value of 85%.[21] The date of diagnosis was the 
date of the first PsA code or date of first disease-modifying anti-rheumatic drug (DMARD) 
prescription in the absence of evidence of an alternative indication for the DMARD (which 
included psoriasis, determined based on methotrexate being prescribed on the same date as a 
psoriasis or dermatology code), whichever was earlier.  
 
Determining smoking, alcohol and BMI status 
Smoking and alcohol consumption status were determined using algorithms developed at the 
University of Bath (see online supplementary text). Smoking status was determined using all 
available medcodes related to smoking and was classified as smoker, ex-smoker or non-smoker. 
Alcohol consumption status was determined using all available medcodes related to 
alcohol/drinking and categorised as heavy drinker (>3.0 units/day), moderate drinker (0.1 – 3.0 
units/day), ex-drinker or non-drinker. Baseline smoking and alcohol consumption status was 
determined based on the associated status covering the psoriasis index date. 
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All Read codes relevant to BMI or weight that could indicate a BMI and/or weight category were 
identified. BMI was classified based on the World Health Organisation BMI categories: <25.0, 
25.0-29.9, 30.0-34.9, ≥35.0. We did not use a separate category for underweight (<18.5) because 
<1% of the study population were within this category. Baseline BMI measurements were 
estimated using a patient’s most recent BMI value in the three years before their psoriasis index 
date. For the secondary analysis the study population was restricted to those who had been 
registered on the CPRD for a minimum of ten years with at least two distinct BMI 
measurements, including one within 6 months of the study end (providing it did not occur before 
their psoriasis index date) and one from a maximum of ten years prior to their study end date. All 
available BMI values between these two BMI records were used. 
 
Potential confounding variables 
Data on potential confounding variables including demographics, severity of psoriasis, diabetes 
and history of trauma were extracted from the CPRD.   In patients who developed PsA during the 
follow-up period, psoriasis severity was classified using data before the date of PsA diagnosis. 
Psoriasis was classified as severe if patients had prescriptions for medicines consistent with the 
treatment of severe disease (e.g. phototherapy, PUVA, or systemic therapies) or evidence of a 
referral to a dermatologist and as mild in the absence of evidence of severe disease. History of 
trauma was restricted to trauma of the bone/joint before the index date. Psoriasis duration was 
determined as the period between psoriasis diagnosis and the earliest of (a) the individual 
developing PsA; (b) the individual or their practice ceasing to contribute data to the CPRD or (c) 
the end of the study period. Demographic variables were extracted at baseline. 
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Statistical Analysis 
Descriptive statistics were used to compare baseline demographics while modifiable life style 
factors associated with the development of PsA were investigated using logistic regression. The 
final models were adjusted for all significant covariates (p <0.05), which was based on their 
contribution to the model as defined by their contribution to the likelihood. Chi-squared tests for 
trend in proportions were used to test linear trends across BMI categories and generalised 
additive models were used to investigate non-linear associations. Due to the extent of missing 
data on BMI in the study population we conducted sensitivity analyses to the proximity of BMI 
measurements to baseline by using 1) nearest available BMI measurement in the three years 
leading up to psoriasis diagnosis 2) nearest available BMI measurement in the five years leading 
up to psoriasis diagnosis and 3) nearest available BMI measurement, irrespective of date of 
occurrence. Non-linear and cumulative effects of BMI were investigated using distributed lag 
non-linear models. All statistical analyses were conducted with R statistical software, version 
3.3.0. 
 
RESULTS 
In total 91,169 incident cases of psoriasis were identified. Cases with a prior diagnosis of PsA (n 
= 863) or the same date of PsA diagnosis (n = 116) were excluded.  From the base population of 
90,189 incident cases of psoriasis, 1,409 developed PsA after their diagnosis of psoriasis. The 
overall incidence of PsA within this population was 2.72 per 1000 person-years (CI95 2.57-2.86). 
Table 1 shows the incidence rates stratified by age and sex with a higher incidence being 
observed in males.   
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There were fewer men than women included in the primary analysis population (48%), which 
was most notable in the highest and lowest BMI categories (Table 2). Lower BMI categories 
were younger, less likely to have a history of trauma and had a longer psoriasis duration than the 
higher BMI categories. Other variables were similarly distributed across BMI categories. At 
baseline,  compared to the psoriasis-only group, those who developed PsA were younger (47 vs 
51 years), were more likely have severe psoriasis (29% vs 12% severe) and had a shorter mean 
duration of psoriasis (3.55 vs 5.75 years) (Table 3).  
 
Influence of modifiable life style factors 
Compared to those with BMIs of <25.0, there was a significantly increased odds of developing 
PsA in those with BMIs of 25.0-29.9, 30.0-34.9 and ≥35.0: OR 1.79 (CI95 1.46 - 2.19), OR 2.10 
(CI95 1.67 - 2.63), and OR 2.68 (CI95 2.09 - 3.43), respectively, (p for trend <0.0001). 
Adjustment for potential confounders marginally attenuated the association with results 
remaining significant (Table 3).  Sensitivity analyses to the proximity of BMI measurements to 
baseline produced identical patterns; an increasing odds of developing PsA with increasing BMI.  
 
No significant associations between past or current smoker compared to non-smoker were found: 
ORadj 0.83 (CI95 0.69 – 1.02) and ORadj 0.94 (CI95 0.76 – 1.16), respectively. When modelled 
along with BMI as an interaction term, the direction of the ORs (and the associated risk of 
developing PsA) for past or current smoker flipped from being negative (protective effect) to 
positive (increased odds), although remained non-significant (ORadj 1.03 (CI95 0.65 – 1.60) and 
1.12 (CI95 0.76 – 1.69), respectively). 
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There was a significantly increased odds of developing PsA in moderate drinkers, but not in ex- 
or heavy drinkers, compared to non-drinkers: ORadj 1.57 (CI95 1.16 – 2.11), ORadj 1.06 (CI95 
0.69 – 1.62) and ORadj 0.94 (CI95 0.56 – 1.58), respectively.  
 
There were 15,627 (15, 410 psoriasis-only and 217 PsA) subjects who fulfilled the study criteria 
for the analysis of non-linear and cumulative effects of BMI. Over a ten year period, linear 
reductions in BMI were associated with a reduction in risk of developing PsA when compared to 
a constant BMI of the same starting value (Figure 1).  Further information can be found in the 
supplementary material. 
 
DISCUSSION 
The overall incidence of PsA in our psoriasis population of 2.72 per 1000 years is similar to 
findings from a similar primary health record based study.[6] In a prospective study from Toronto 
the incidence rate was 10 times higher, possibly explained as all patients in the Toronto cohort 
underwent an annual review by a rheumatologist.[24] The Toronto cohort also recruited over 65% 
of patients from phototherapy centres, likely capturing those with more severe psoriasis which 
has been found to be associated with an increased risk of PsA.[24, 25] Nevertheless, the difference 
could suggest an under-ascertainment of PsA within the CPRD, providing support for studies 
reporting a high burden of undiagnosed PsA within patients with psoriasis.[26]  
 
Risk factors for the development of PsA for which there is good evidence include nail psoriasis, 
psoriasis severity and obesity as well as genetic factors such as HLA-B27.[1, 27] Of these factors 
the only modifiable lifestyle factor is obesity. Here we have shown for the first time that losing 
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weight over time, could reduce the risk of developing PsA in a population with documented 
psoriasis. This change in risk can be demonstrated with the use of a BMI risk calculator.  
 
Although studies investigating the association between changes in BMI and the development of 
PsA among people with psoriasis are limited in number, all have found an association between 
increased BMI and increased risk of PsA. One study found that BMI in early adulthood increased 
the risk of PsA, but did not find an association between current BMI and PsA.[5] Two studies 
found an increased risk of PsA correlated to BMI with associations existing in a dose-dependent 
fashion.[6, 7] Two studies have investigated the effect of obesity at multiple time points.[6, 7] The 
first of these investigated the effect of BMI over the 10 years following psoriasis diagnosis and 
found that those in higher BMI categories had a higher risk of developing PsA.[6] The second 
study found a graded positive association between gains in weight and the risk in developing 
PsA.[7] Since the effect of obesity on the risk of developing PsA may in fact occur with some 
delay and change over time, our analysis took into account both updated BMI measurements 
over time and the possible non-linear and cumulative effects of BMI, which has not previously 
been investigated. 
 
There are mechanisms to explain how obesity may be a contributory causative factor for PsA.  
For instance adipose tissue is a source of inflammatory mediators such as adipokines and 
proinflammatory cytokines including TNF- and IL-6 that together with other genetic, 
environmental and immunological factors may trigger the development of PsA in susceptible 
individuals with psoriasis.[28] Microtrauma at entheseal sites is postulated as being an important 
initiating pathogenic event for the development of PsA, and may be enhanced with increasing 
body weight.[29] Unloading mechanical stress on hind limbs prevents the onset of enthesitis in a 
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susceptible mouse model.[30] Furthermore, radiological evidence of enthesitis was reported as 
more frequent in overweight patients with PsA, and even more so in obese patients than in those 
with normal BMI.[31] 
 
We have confirmed findings from previous studies that moderate alcohol intake was associated 
with an increased the risk of developing PsA in people with psoriasis, although the association 
did not hold true for the subgroups of ex-drinkers or heavy drinkers. We also found that severity 
of psoriasis was associated with an increase in the risk of developing PsA consistent with most 
previous studies. These findings were based on data extracted at psoriasis onset and unlike BMI 
status we were not able to assess over time. A limiting factor in our study is the lack of data on 
secondary care prescribing in the CPRD such as the use of biological agents that may act as 
confounders or have an interaction with both alcohol intake and psoriasis severity. 
 
Findings of the association between smoking and risk of PsA among people with psoriasis are 
inconsistent. For example, Tey et al.[15] found no association between smoking and PsA, two 
studies suggest that smoking protects against PsA,[10, 11] while Li et al.[9]  found that smoking had 
an increased risk of PsA. A recent study by Nguyen et al.[32] explored this ‘smoking paradox’ and 
concluded that traditional study design and analytical methods could result in a risk factor 
paradox in the context of smoking and risk of PsA among patients with psoriasis. While we 
found no association between smoking status and the development of PsA in people with 
psoriasis, further analysis revealed that the effect of smoking on the risk of PsA was possibly 
mediated through the effect of BMI on PsA, i.e. the protective effect of smoking may be 
associated with lower BMI amongst smokers.  
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Strengths of our study include its population-based nature, the large number of psoriasis patients 
and the previous validation of the codes used to identify psoriasis and PsA. The inclusion of only 
incident psoriasis patients was an advantage when looking at the temporal relationship of BMI 
and the risk of PsA. A shortcoming is that lifestyle data tends to be opportunistically recorded in 
the CPRD and those with non-missing lifestyle data may be unrepresentative of the general 
population and restriction to those with complete data may result in biased analyses.[33, 34] In 
addition, psoriasis severity was determined based on referrals to a dermatologist or on 
prescriptions for medicines consistent with the treatment of severe disease. It is possible that 
psoriasis severity could be associated with treating PsA when the code for PsA has not been 
entered. Moreover, by using Read codes validated in a similar database we hope to have limited 
bias due to case ascertainment.[21] 
 
In conclusion, the findings of this study add to the growing evidence that increased BMI is 
associated with an increased risk of PsA. Furthermore a reduction in BMI over time, albeit not 
necessarily intentional, was associated with a reduction in the risk of PsA. While more studies 
are needed to investigate intentional weight loss on the risk of developing PsA, weight reduction 
amongst obese people with psoriasis may have the potential ability to prevent their excess risk of 
PsA while providing additional health benefits, including reduced cardiovascular and mortality 
risks.[35] 
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Tables and Figures 
Table 1 Incidence Age and sex specific incidence of PsA within the incident psoriasis cohort in the CPRD, per 10 000 person-years. 
  Males Females All 
Age at 
psoriasis 
diagnosis PsA cases PYs IR 95% CI PsA cases PYs IR 95% CI PsA cases PYs IR 95% CI 
18-29 72 29421 2.45 1.88 - 3.01 66 32252 2.05 1.55 - 2.54 138 61673 2.24 1.86 - 2.61 
30-39 151 36628 4.12 3.47 - 4.78 105 39135 2.68 2.17 - 3.2 256 75763 3.38 2.97 - 3.79 
40-49 213 47763 4.46 3.86 - 5.06 148 45772 3.23 2.71 - 3.75 361 93535 3.86 3.46 - 4.26 
50-59 171 47786 3.58 3.04 - 4.11 176 47007 3.74 3.19 - 4.3 347 94793 3.66 3.28 - 4.05 
60-69 103 46661 2.21 1.78 - 2.63 127 48433 2.62 2.17 - 3.08 230 95094 2.42 2.11 - 2.73 
70-79 28 31270 0.9 0.56 - 1.23 31 35853 0.86 0.56 - 1.17 59 67123 0.88 0.65 - 1.1 
80-89 7 12046 0.58 0.15 - 1.01 9 18635 0.48 0.17 - 0.8 16 30681 0.52 0.27 - 0.78 
All 745 251574 2.96 2.75 - 3.17 664 267087 2.49 2.3 - 2.68 1409 518661 2.72 2.57 - 2.86 
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Table 2 Baseline characteristics of study participants. All variables were based on those 
measured at the time of psoriasis diagnosis, except for BMI which was based on nearest 
available BMI measurement in the three years leading up to psoriasis diagnosis.   
 
 
 
All Psoriasis only PsA 
 
(n=90189) (n=88780) (n=1409) 
Sex (%)    
Female (Reference) 46590 (52) 45926 (52) 664 (47) 
Male 43599 (48) 42854 (48) 745 (53) 
Age, mean (SD), years 48.34 (18.22) 48.51 (18.29) 44.70 (13.88) 
Psoriasis duration, mean (SD), years 5.71 (4.10) 5.75 (4.11) 3.55 (3.36) 
History of Trauma, (n, %) 17206 (19) 16941 (19) 265 (19) 
Diabetes, (n, %)    
None (Reference) 81201 (90) 79953 (90) 1248 (89) 
Type I 251 (0) 250 (0) 1 (0) 
Type II 8737 (10) 8577 (10) 160 (11) 
Psoriasis severity, (n, %)    
Mild (Reference) 78698 (87) 77697 (88) 1001 (13) 
Severe  11491 (13) 11083 (71) 408 (29) 
BMI category, (n, %)    
<25 (Reference) 15519 (17) 15384 (17) 135 (10) 
25.0-29.9 15841 (18) 15603 (18) 238 (17) 
30.0-34.9 8980 (10) 8818 (10) 162 (11) 
35>= 5854 (6) 5728 (6) 126 (9) 
Missing 43995 (49) 43247 (49) 748 (53) 
Smoking status, (n, %)    
Non-smoker (Reference) 38452 (43) 37808 (42) 644 (46) 
Ex-smoker 25039 (28) 24646 (28) 393 (28) 
Current smoker 25133 (28) 24768 (28) 365 (26) 
Missing 1564 (2) 1558 (2) 7 (0) 
Alcohol status, (n, %)    
Non-drinker (Reference) 9883 (11) 9745 (11) 138 (10) 
Moderate drinker 60002 (67) 58982 (66) 1020 (72) 
Heavy drinker 3995 (4) 4370 (5) 60 (4) 
Ex-drinker 4430 (5) 3942 (5) 53 (4) 
Missing 11879 (13) 11741 (13) 138 (10) 
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Table 3 Associations between modifiable life style factors and PsA. 
 
 Unadjusted Adjusted† 
 
OR CI95 P OR CI95 P 
BMI categorya       
<25 (Reference) 1.00 - - 1.00 - - 
25.0-29.9 1.79 1.46 - 2.19 <0.0001 1.76 1.41 - 2.19 <0.0001 
30.0-34.9 2.10 1.67 - 2.63 <0.0001 2.04 1.60 - 2.60 <0.0001 
35>= 2.68 2.09 - 3.43 <0.0001 2.42 1.85 – 3.16 <0.0001 
       
Smoking statusb          
Non-smoker (Reference) 1.00 - - 1.00 - - 
Ex-smoker 0.92 0.77 – 1.10 0.3650 0.83 0.69 - 1.02 0.0733 
Current smoker 0.95 0.78 – 1.15 0.5850 0.94 0.76 - 1.16 0.5442 
       
Alcohol statusc             
Non-drinker (Reference) 1.00 - - 1.00 - - 
Moderate drinker 1.53 1.40 – 2.06 0.004 1.57 1.16 – 2.11 0.0033 
Heavy drinker 1.20 0.72 – 2.00 0.4713 0.94 0.56 - 1.58 0.8216 
Ex-drinker 1.25 0.82 – 1.90 0.2982 1.06 0.69 - 1.62 0.7848 
 
†The following covariates were considered for adjustment in the model; sex, age, psoriasis duration, history of trauma, diabetes, 
psoriasis severity and, where appropriate, BMI, smoking and alcohol. The final models were adjusted for all significant 
covariates (p <0.05); aAdjusted for age, psoriasis duration, psoriasis severity and alcohol status bAdjusted for age, psoriasis 
duration, psoriasis severity and BMI category cAdjusted for age, psoriasis duration, psoriasis severity, alcohol status and BMI 
category. Results were robust to sensitivity analysis in which psoriasis severity was restricted to evidence of a prescription for a 
treatment consistent with severe disease only and did not include dermatology referrals. 
 
 
Figure 1 Risk calculator for BMI and developing PsA. Here risk, measured as an odds ratio, was 
estimated using a Distributed lag non-linear model, which represents a modelling framework to 
flexibly describe associations showing potentially non-linear and delayed effects. This figure 
shows the differences between the cumulative risk associated with a linear change in BMI over a 
10 year period and that with remaining at a constant BMI (with each case starting from the same 
value). The change in risk is the difference between the risks at ten years from the two cases, 
expressed as a percentage (of BMI remaining constant). Positive changes (shown in red) indicate 
an increase in risk with negative changes (in green) indicating reduced risk. For example, 
consider an individual with a BMI of 30 and two different scenarios: (i) they reduce their BMI 
from 30 to 25; (ii) they remain at a constant BMI of 30. Compared to remaining at a constant 
BMI of 30, reducing BMI from 30 to 25 reduces the cumulative risk of developing PsA by 13%.  
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KEY MESSAGES 
 
What’s already known about this topic? 
 There is some evidence that increased BMI is associated with an increased risk of 
developing PsA and conflicting results surrounding the relationship between smoking and 
the development of PsA among patients with psoriasis. 
 
What does this study add? 
 Using non-linear and lagged effect of BMI measured over time we have shown that 
reducing BMI may be associated with a reduction in the risk of developing PsA 
 We have found no evidence that smoking alters the risk of developing PsA in patients 
with psoriasis 
 
